Clinical Trial Update: A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program [Phase 3]

View source ↗

Summary

Phase IIIb open-label extension study evaluating long-term safety of PRN intravitreal DE-109 in non-infectious uveitis of the posterior segment; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-infectious Uveitis of the Posterior Segment of the Eye

Drugs mentioned

• DE-109 (DE-109)

Snippet

Sponsor: Santen Inc. | Conditions: Non-Infectious Uveitis of the Posterior Segment of the Eye | Phase 3 | Status: COMPLETED | Results posted: 2020-02-12